Mei Ri Jing Ji Xin Wen·2026-02-24 14:30Group 1 - The core viewpoint of the articles highlights the continued high demand for Chinese innovative drugs in global markets, with significant business development (BD) transactions occurring in early 2026, indicating a strong growth trajectory for the industry [1][2]. - As of February 15, 2026, there have been 39 license-out transactions for Chinese innovative drugs, with an upfront payment of approximately $2.953 billion and a total value exceeding $49 billion, surpassing one-third of the total amount for 2025 [1]. - Morgan Stanley's report emphasizes a positive long-term outlook for the Chinese pharmaceutical industry, identifying "catalysts" as a key theme, with expectations for numerous catalysts in 2026 that will enhance the global value of domestic pharmaceutical assets [2]. Group 2 - Morgan Stanley specifically mentions that 2025 saw a total BD transaction amount of $135.7 billion for Chinese innovative drugs, surpassing the U.S. for the first time, with 2026 showing even stronger growth as the first 49 days of transactions exceeded any single quarter in 2025 [2]. - The report highlights Hengrui Medicine as a preferred investment target, predicting accelerated sales growth in 2026 and a positive trend in new cooperative transactions, which are crucial for realizing milestone payments [2]. - The transformation of Kangzhe Pharmaceutical towards innovative drugs is noted, with the approval of a targeted drug for vitiligo, indicating a significant step in the company's transition and growth strategy [3]. Group 3 - Despite the ongoing BD transaction boom, the innovative drug sector is experiencing a market downturn, with the Hong Kong innovative drug ETF dropping 0.78% after the Spring Festival, indicating a disconnect between market sentiment and fundamentals [4]. - The focus of BD transactions in 2026 is shifting towards early-stage research projects, with over 50% of the 39 transactions being in preclinical stages, reflecting a strategic pivot in the industry [5]. - Companies like Kangfang Biotech are optimistic about the global impact of Chinese innovative drugs, aiming to expand their global footprint and enhance their international presence in drug development [5].